Skip to main content
Genetic Testing and Molecular Biomarkers logoLink to Genetic Testing and Molecular Biomarkers
. 2014 Apr 1;18(4):245–252. doi: 10.1089/gtmb.2013.0368

Roles of Three Common VEGF Polymorphisms in the Risk of Age-Related Macular Degeneration

Yuqing Liu 1,, Siqing Hou 1, Weihua Lang 1, Dongshu Dai 1, Zhixue Wang 1, Xiangning Ji 1, Kun Li 1, Xi Zhang 1, Yuanyuan Zou 1, Jingxian Wang 1
PMCID: PMC3976594  PMID: 24689893

Abstract

Associations between vascular endothelial growth factor (VEGF) polymorphisms (rs833061, rs1413711, and rs3025039) and risk of age-related macular degeneration (AMD) have been extensively studied, but the currently available results are contentious rather than conclusive. Therefore, we performed the present meta-analysis to further assess the associations. Literature search in PubMed, Embase, and Web of Science databases was conducted until April 2013. The strength of the associations between VEGF polymorphisms and AMD risk was estimated by pooled odds ratios (ORs) and 95% confidence intervals (CIs). Both models of fixed effects and random effects were performed to summarize the pooled ORs. All data were analyzed by Stata software 12.0. The meta-analysis results based on nine case–control studies with 2427 cases and 2037 controls showed that rs833061 had protective effects on AMD risk (TT vs. CT+CC: OR=0.58, 95% CI=0.41–0.81), whereas rs1413711 (TT vs. CT+CC: OR=1.46, 95% CI=1.10–1.93) and rs3025039 (TT vs. CC: OR=1.87, 95% CI=1.15–3.02; TT vs. CT+CC: OR=2.09, 95% CI=1.30–3.37) represented as risk factors for AMD. Subgroup analysis by ethnicity suggested significantly reduced risk in Caucasians (TT vs. CT+CC: OR=0.60, 95% CI=0.36–0.99; T vs. C: OR=0.89, 95% CI=0.78–1.00) and Asians (TT+CT vs. CC: OR=0.57, 95% CI=0.34–0.96; TT vs. CT+CC: OR=0.54, 95% CI=0.33–0.90) for rs833061, yet elevated risk in Caucasians (TT vs. CT+CC: OR=2.05, 95% CI=1.24–3.38) for rs1413711 and in Asians (TT vs. CC: OR=2.06, 95% CI=1.24–3.43; TT vs. CC: OR=2.34, 95% CI=1.42–3.89) for rs3025039. In stratified analysis by type of AMD, rs833061 was observed to decrease wet AMD risk, while rs1413711 and rs3025039 were found to increase the risk of wet AMD. Based on the currently available data, this meta-analysis suggests that the VEGF polymorphisms may be associated with risk of AMD, particularly wet AMD.

Introduction

Age-related macular degeneration (AMD), a degenerative disease of the retina leading to progressive impairment of central vision, is the major cause of irreversible vision loss among older populations in developed countries (Jager et al., 2008). There are two subtypes of AMD: nonexudative (dry or atropic) AMD and exudative (wet or neovascular). Exudative AMD is characterized by geographic atrophy or the development of choroidal neovascularization, where abnormal blood vessels grow from the choroid underneath the retina and leak, thus causing rapid deterioration in central vision (Ferris et al., 2005). AMD is a complex disorder known to result from environmental and genetic factors (Seddon et al., 2011). While an array of genes have been identified as susceptibility factors to the disease (Ting et al., 2009; Yachimski et al., 2009), the mechanism of AMD progression has not been well understood.

Tumor growth progresses from the formation of blood vessels, a process known as angiogenesis (Folkman, 1971). Vascular endothelial growth factor (VEGF) is a fundamental meditator of angiogenesis, vasculogenesis, and lymphangiogenesis in normal and pathological cells (Ferrara, 1999). VEGF is essential for retinal health due to its involvement in vascular development, survival of nascent retinal vessels, and maintenance of stable mature vessels (Penn et al., 2008). Many retinal diseases, including the highly prevalent AMD, have been reported to be correlated with elevated expression of VEGF (Penn et al., 2008).

The human VEGF gene, located on chromosome 6p21.3, is comprised of eight exons and seven introns, with the coding region spanning ∼14 kb (Vincenti et al., 1996; Ferrara et al., 2003; Goncalves et al., 2010). Polymorphisms of the VEGF gene have been substantially investigated in AMD, yet the data obtained from the investigations remain contentious and ambiguous. For example, a study containing seven single-nucleotide polymorphisms (SNPs) of the VEGF gene conducted in an Anglo-Celtic subpopulation demonstrated no associations between the studied SNPs and AMD (Richardson et al., 2007). However, a subsequent study of a Chinese population indicated VEGF gene is relevant to wet AMD (Lin et al., 2008). The similar conflicting results were also presented in recently published meta-analyses (Lu et al., 2012; Huang et al., 2013).

Based on the importance of VEGF in AMD pathogenesis and contradictory data on the role of VEGF SNPs in AMD risk, we sought to derive compelling evidence for the association through a meta-analysis of all eligible case–control studies concerning the associations between three common SNPs (rs833061, rs1413711, and rs3025039) and the risk of AMD.

Materials and Methods

Search strategy

We carried out a literature search in PubMed (www.ncbi.nlm.nih.gov/pubmed), Embase (http://202.106.73.6:8080/medlib/s/com/embase/www/G.http/home), and Web of Science (www.thomsonscientific.com.cn/productsservices/webofscience/), covering all articles addressing the associations between the three polymorphisms of VEGF gene and AMD risk (up to April 2013). The search strategy used a combination of the following terms: vascular endothelial growth factor or VEGF; rs833061, rs1413711, and rs3025039 or −460T/C, +674C/T, and +936C/T; age-related macular degeneration or AMD. Besides the database search, the reference lists of the retrieved articles were also screened for other potential articles.

We defined the following criteria for inclusion: (1) used a case–control study design; (2) evaluated one of the three polymorphisms of VEGF gene and AMD risk; (3) contained enough genotype data to estimate odds ratios (ORs) and 95% confidence intervals (CIs). The major reasons for exclusion were (1) case-only study; (2) overlapping data; (3) insufficient information on genotype frequency; (4) review articles and comment letters.

Data extraction

Data were independently retrieved in duplicate by two authors according to the defined inclusion criteria to ensure the accuracy of the data. For each study, the following information was recorded: first author, publication year, country of origin, sources of AMD cases and controls, study type, ethnicity, numbers of cases and controls, and genotype frequencies of cases and controls.

Statistical analysis

The associations between VEGF polymorphisms and AMD risk were estimated by calculating pooled ORs and 95% CIs under homozygote model TT versus CC, dominant model TT+CT versus CC, recessive model TT versus CT+CC, allele model T versus C and heterozygote model CT versus CC. The significance of the summary ORs was checked by Z test (p<0.10 was deemed significant). The χ2-based Q statistic and I2-based Q statistic test (Higgins et al., 2003) were performed to evaluate variations due to heterogeneity rather than chance. Heterogeneity was considered statistically significant when p<0.10 or I2>50%. A random-effects model (DerSimonian-Laird method) (DerSimonian and Laird, 1986) was used if obvious heterogeneity was indicated, or the fixed-effects model (Mantel–Haenszel method) (Mantel and Haenszel, 1959) was applied to calculate pooled effect estimates. Stratified analyses were also performed by types of AMD and ethnicity. A χ2 test was performed to determine the Hardy–Weinberg equilibrium (HWE) of the control subjects and p<0.10 suggested representative of deviation from HWE. Publication bias was detected by Begg's funnel plots and Egger's test (Egger et al., 1997). Asymmetry of the funnel plot or p<0.10 indicated a potential publication bias across the included studies. The leave-one-out sensitivity analysis by repeated meta-analyses of excluding each study was conducted to reflect the influence of the excluded study to the overall summary ORs. All data were done with Stata software (version 12.0; Stata Corp LP, College Station, TX).

Results

Characteristics of studies

Two hundred sixteen potentially relevant studies were recovered by literature search in PubMed, Embase, and Web of Science. All retrieved articles were examined by reading titles, abstracts, and full texts to check the eligibility for this meta-analysis. After careful screening, nine case–control studies (Churchill et al., 2006; Richardson et al., 2007; Lin et al., 2008; Janik-Papis et al., 2009; Szaflik et al., 2009; Galan et al., 2010; Qu et al., 2011; Almeida et al., 2012; Jiang et al., 2013) with 2427 cases and 2037 controls were finally included in the meta-analysis (Fig. 1). Among them, five studies were (1150 cases and 615 controls) for rs833061 SNP, four studies (554 cases and 554 controls) for rs1413711 SNP, and four studies (723 cases and 868 controls) for rs3025039 SNP (two studies contained three SNPs). Main characteristics of the included studies are summarized in Table 1.

FIG. 1.

FIG. 1.

Studies identified with criteria for inclusion and exclusion.

Table 1.

Characteristics of Studies Included in the Meta-Analysis

          Cases Controls  
First author, year Type Ethnicity Source SNP Study size CC CT TT C T Study size CC CT TT C T HWE
Richardson, 2007a Total Caucasian PB rs833061 566 153 259 154 565 567 157 39 78 40 156 158 0.937
Richardson, 2007a Dry Caucasian PB rs833061 100 30 43 27 103 97 157 39 78 40 156 158 0.937
Richardson, 2007a Wet Caucasian PB rs833061 336 86 158 92 330 342 157 39 78 40 156 158 0.937
Lin, 2008a Total Asian HB rs833061 190 8 66 116 82 298 80 4 60 116 68 92 <0.001
Lin, 2008a Dry Asian HB rs833061 104 6 38 60 50 158 80 4 60 116 68 92 <0.001
Lin, 2008a Wet Asian HB rs833061 86 2 28 56 32 140 80 4 60 116 68 92 <0.001
Janik-Papis, 2009a Total Caucasian HB rs833061 265 26 191 48 243 287 134 11 63 60 85 183 0.323
Janik-Papis, 2009a Dry Caucasian HB rs833061 88 8 67 13 83 93 134 11 63 60 85 183 0.323
Janik-Papis, 2009a Wet Caucasian HB rs833061 177 18 124 35 160 194 134 11 63 60 85 183 0.323
Szaflik, 2009 Wet Caucasian HB rs833061 100 8 78 14 94 106 104 11 56 37 78 130 0.129
Qu, 2011 Wet Asian HB rs833061 159 20 58 81 98 220 140 9 50 81 68 212 0.733
Churchill, 2006 Wet Caucasian PB rs1413711 45 17 18 10 52 38 94 19 54 21 92 96 0.147
Lin, 2008a Total Asian HB rs1413711 190 57 80 53 194 186 180 50 85 45 185 175 0.462
Lin, 2008a Dry Asian HB rs1413711 104 29 46 29 104 104 180 50 85 45 185 175 0.462
Lin, 2008a Wet Asian HB rs1413711 86 28 34 24 90 82 180 50 85 45 185 175 0.462
Qu, 2011 Wet Asian HB rs1413711 159 81 58 20 220 98 140 81 50 9 212 68 0.733
Almeida, 2012a Total Caucasian HB rs1413711 160 65 66 29 196 124 140 67 65 8 199 81 0.127
Almeida, 2012a Dry Caucasian HB rs1413711 36 14 14 8 42 30 140 67 65 8 199 81 0.127
Almeida, 2012a Wet Caucasian HB rs1413711 124 51 52 21 154 94 140 67 65 8 199 81 0.127
Lin, 2008a Total Asian HB rs3025039 190 120 58 12 298 82 280 134 42 4 410 150 <0.001
Lin, 2008a Dry Asian HB rs3025039 114 75 27 12 177 51 280 134 42 4 410 150 <0.001
Lin, 2008a Wet Asian HB rs3025039 86 45 31 10 121 51 280 134 42 4 410 150 <0.001
Galan, 2010 Total Caucasian HB rs3025039 226 175 48 3 398 54 248 190 54 4 434 62 0.942
Qu, 2011 Wet Asian HB rs3025039 159 114 33 12 261 57 140 92 40 8 224 56 0.249
Jiang, 2013a Total Asian HB rs3025039 200 132 50 18 314 86 200 138 55 7 331 69 0.603
Jiang, 2013a Dry Asian HB rs3025039 49 32 13 4 77 21 200 138 55 7 331 69 0.603
Jiang, 2013a Wet Asian HB rs3025039 99 66 25 8 157 41 200 138 55 7 331 69 0.603
a

One study included several single-nucleotide polymorphisms (SNPs).

HWE, Hardy–Weinberg equilibrium; PB, population-based; HB, hospital-based.

Quantitative synthesis

Table 2 shows the results of the meta-analysis on the associations between VEGF polymorphisms and risk of AMD. For rs833061, a reduced AMD risk associated with the recessive model (TT vs. CT+CC: OR=0.58, 95% CI=0.41–0.81) (Fig. 2) was observed in the general analysis. In the stratified analysis based on ethnicity, we found a decreased risk of AMD in Asians under the dominant model (TT+CT vs. CC: OR=0.57, 95% CI=0.34–0.96) and the recessive model (TT vs. CT+CC: OR=0.54, 95% CI=0.33–0.90). However, a borderline association was indicated in Caucasians under the recessive model (TT vs. CT+CC: OR=0.60, 95% CI=0.36–0.99) and the allele model (T vs. C: OR=0.89, 95% CI=0.78–1.00). Stratifying the overall population by type of AMD showed that the recessive model (TT vs. CT+CC: OR=0.61, 95% CI=0.41–0.91) reduced risk of wet AMD. But none of the genetic models were found to be associated with dry AMD.

Table 2.

Meta-analysis of VEGF Polymorphisms (rs833061, rs1413711, and rs3025039) and Risk of Age-Related Macular Degeneration

  TT vs. CC TT+CT vs. CC TT vs. CT+CC Allele T vs. Allele C CT vs. CC
Variables OR (95% CI) ph I2 OR (95% CI) ph I2 OR (95% CI) ph I2 OR (95% CI) ph I2 OR (95% CI) ph I2
rs833061
Caucasian 0.88 (0.68–1.15) 0.929 0.0% 0.98 (0.84–1.15) 0.998 0.0% 0.60 (0.36–0.99) 0.002 77.1% 0.89 (0.78–1.00) 0.575 0.0% 1.00 (0.83–1.21) 0.977 0.0%
Asian 0.94 (0.73–1.21) 0.936 0.0% 0.57 (0.34–0.96) 0.002 83.5% 0.54 (0.33–0.90) 0.012 77.3% 1.17 (0.88–1.56) 0.068 62.8% 0.92 (0.67–1.27) 0.954 0.0%
Dry 0.90 (0.65–1.24) 0.848 0.0% 0.73 (0.43–1.25) 0.003 82.4% 0.52 (0.26–1.04) 0.007 79.6% 0.99 (0.74–1.34) 0.069 62.5% 0.95 (0.71–1.27) 0.872 0.0%
Wet 0.92 (0.74–1.15) 0.943 0.0% 0.85 (0.64–1.12) 0.011 69.2% 0.61 (0.41–0.92) 0.004 74.0% 0.96 (0.81–1.14) 0.099 48.7% 0.99 (0.81–1.21) 0.982 0.0%
All 0.91 (0.76–1.10) 0.993 0.0% 0.80 (0.63–1.03) 0.000 73.1% 0.58 (0.41–0.81) 0.000 74.1% 0.97 (0.84–1.12) 0.067 47.0% 0.98 (0.83–1.15) 0.998 0.0%
rs1413711
Caucasian 1.83 (0.69–4.88) 0.041 68.6% 1.03 (0.77–1.38) 0.517 0.0% 2.05 (1.24–3.38) 0.080 60.5% 1.17 (0.92–1.49) 0.186 40.6% 0.93 (0.67–1.29) 0.616 0.0%
Asian 1.16 (0.80–1.68) 0.368 0.1% 1.03 (0.82–1.29) 0.741 0.0% 1.24 (0.88–1.75) 0.476 0.0% 1.07 (0.89–1.29) 0.529 0.0% 0.98 (0.75–1.29) 0.801 0.0%
Dry 1.72 (0.55–5.36) 0.061 71.4% 1.04 (0.76–1.43) 0.657 0.0% 1.40 (0.88–2.23) 0.036 77.2% 1.12 (0.87–1.45) 0.251 24.1% 0.99 (0.67–1.45) 0.923 0.0%
Wet 1.36 (0.76–2.42) 0.093 53.2% 1.02 (0.82–1.27) 0.635 0.0% 1.49 (1.04–2.12) 0.181 38.5% 1.10 (0.92–1.32) 0.299 18.3% 0.95 (0.47–1.22) 0.695 0.0%
All 1.42 (0.91–2.23) 0.077 49.6% 1.03 (0.86–1.23) 0.860 0.0% 1.46 (1.10–1.93) 0.100 45.9% 1.11 (0.96–1.28) 0.415 0.1% 0.96 (0.78–1.18) 0.916 0.0%
rs3025039
Caucasian 0.82 (0.18–3.70) 0.96 (0.64–1.46) 0.82 (0.18–3.72) 0.96 (0.65–1.41) 0.97 (0.63–1.49)
Asian 2.06 (1.24–3.43) 0.232 28.4% 1.38 (0.87–2.17) 0.003 74.6% 2.34 (1.42–3.89) 0.190 34.8% 0.93 (0.78–1.13) 0.056 56.6% 1.06 (0.83–1.36) 0.282 20.9%
Dry 1.58 (0.57–4.39) 0.387 0.0% 1.43 (0.96–2.14) 0.312 2.2% 1.89 (0.68–5.23) 0.613 0.0% 0.73 (0.53–1.02) 0.020 81.4% 1.07 (0.70–1.64) 0.840 0.0%
Wet 2.24 (1.24–4.05) 0.101 56.4% 1.37 (0.65–2.90) 0.001 86.4% 2.50 (1.39–4.49) 0.059 64.8% 1.06 (0.84–1.33) 0.589 0.0% 1.05 (0.78–1.43) 0.082 60.1%
All 1.87 (1.15–3.02) 0.230 27.2% 1.29 (0.88–1.89) 0.003 72.1% 2.09 (1.30–3.37) 0.168 35.9% 0.94 (0.79–1.11) 0.101 45.8% 1.04 (0.84–1.28) 0.395 3.4%

ph, p-value of heterogeneity test; CI: confidence interval; OR, odds ratio; VEGF, vascular endothelial growth factor.

FIG. 2.

FIG. 2.

Meta-analysis of the association between rs833061 and AMD risk stratified by ethnicity under TT versus CT+CC. Squares represent the point estimate of effect for each study, and horizontal lines through the squares represent 95% CIs. The area of each square reflects the weight assigned to that study. The center of the diamond represents the summary point estimate of effect, and the width of the diamond represents the 95% CI of the summary point estimate of effect. *Represents an independent population in a single article. AMD, age-related macular degeneration; CIs, confidence intervals.

For rs1413711, overall, we found that the recessive model (TT vs. CT+CC: OR=1.46, 95% CI=1.10–1.93) (Fig. 3) was significantly associated with an increased AMD risk. Similarly, stratified analyses showed the TT genotype conferred 2.05-fold risk to AMD susceptibility in Caucasians and 1.49-fold risk to wet AMD, compared to the CT+CC genotypes (OR=2.05, 95% CI=1.24–3.38; OR=1.49, 95% CI=1.04–2.12, respectively), but not in Asians or dry AMD (Table 2).

FIG. 3.

FIG. 3.

Meta-analysis of the association between rs1413711 and AMD risk stratified by ethnicity under TT versus CT+CC. Squares represent the point estimate of effect for each study, and horizontal lines through the squares represent 95% CIs. The area of each square reflects the weight assigned to that study. The center of the diamond represents the summary point estimate of effect, and the width of the diamond represents the 95% CI of the summary point estimate of effect. *Represents an independent population in a single article.

For rs3025039, statistical evidence for significant association between this polymorphism and AMD risk was indicated in overall population under the homozygote model (TT vs. CC: OR=1.87, 95% CI=1.15–3.02) (Fig. 4) and the recessive model (TT vs. CT+CC: OR=2.09, 95% CI=1.30–3.37) (Fig. 5). The two genetic models also showed significantly elevated risk in Asians (TT vs. CC: OR=2.06, 95% CI=1.24–3.43; TT vs. CC: OR=2.34, 95% CI=1.42–3.89) and in wet AMD (TT vs. CC: OR=2.24, 95% CI=1.24–4.05; TT vs. CC: OR=2.50, 95% CI=1.39–4.49) (Table 2).

FIG. 4.

FIG. 4.

Meta-analysis of the association between rs3025039 and AMD risk stratified by ethnicity under TT versus CC. Squares represent the point estimate of effect for each study, and horizontal lines through the squares represent 95% CIs. The area of each square reflects the weight assigned to that study. The center of the diamond represents the summary point estimate of effect, and the width of the diamond represents the 95% CI of the summary point estimate of effect. *Represents an independent population in a single article.

FIG. 5.

FIG. 5.

Meta-analysis of the association between rs3025039 and AMD risk stratified by ethnicity under TT versus CT+CC. Squares represent the point estimate of effect for each study, and horizontal lines through the squares represent 95% CIs. The area of each square reflects the weight assigned to that study. The center of the diamond represents the summary point estimate of effect, and the width of the diamond represents the 95% CI of the summary point estimate of effect. *Represents an independent population in a single article.

Test of heterogeneity and sensitivity analysis

The Q-test and I2 statistics were used to test heterogeneity among the studies. Significant heterogeneity was observed in the dominant model, recessive model, and allele model for rs833061; weak heterogeneity was indicated in the homozygote model for rs1413711; and obvious between-study heterogeneity in the dominant model for rs3025039 (p<0.10 or I2>50%). The subsequent sensitivity analysis identified Lin et al. (2008) and Almeida et al. (2012) were potential sources of heterogeneity. The corresponding ORs were not altered quantitively by excluding the two studies, suggesting our results were statistically stable and reliable.

Publication bias

The Begg's funnel plot and Egger's test were performed to determine the publication bias in the reports included in this meta-analysis. The symmetrical shape of funnel plots and the p-values of Egger's test showed no evidence of significant publication bias (TT vs. CC: p=0.523 for rs833061; TT+CT vs. CC: p=0.303 for rs1413711; TT vs. CC: p=0.201 for rs3025039) (Figs. 6–8).

FIG. 6.

FIG. 6.

Begg's funnel plot for publication bias test (TT vs. CC for rs833061). Each point represents a separate study for the indicated association. Log OR natural logarithm of OR. Horizontal line mean effect size. OR, odds ratio.

FIG. 7.

FIG. 7.

Begg's funnel plot for publication bias test (TT+CT vs. CC for rs1413711). Each point represents a separate study for the indicated association. Log OR natural logarithm of OR. Horizontal line mean effect size.

FIG. 8.

FIG. 8.

Begg's funnel plot for publication bias test (TT vs. CC for rs3025039). Each point represents a separate study for the indicated association. Log OR natural logarithm of OR. Horizontal line mean effect size.

Discussion

Based on all available published studies to date, we performed a meta-analysis with an objective to examine the associations between VEGF polymorphisms and susceptibility to AMD. The results based on the pooled data by both fixed and random effects models suggested different overall effects of the VEGF polymorphisms on risk of AMD. Significantly lowered risk was indicated in rs833061, while rs1413711 and rs3025039 showed an obviously increased risk. In addition, the predisposition to AMD related to the three polymorphisms greatly differed in the studied ethnic groups. For rs833061, both Caucasians and Asians were found to be relevant to reduced risk of AMD, whereas rs1413711 showed significantly elevated risk in Caucasians rather than Asians and rs3025039 implicated an association in Asians, but not in Caucasians. In stratified analysis by type of AMD, all of the VEGF polymorphisms showed significant associations in wet AMD only.

Genetic factors play important roles in the pathogenesis of AMD. Recently, a number of investigators take great interest in the associations between VEGF polymorphisms and AMD susceptibility. However, the associations are conflicting rather than conclusive. VEGF polymorphisms were reported to be positively relevant (Almeida et al., 2012), inversely relevant (Janik-Papis et al., 2009), or irrelevant (Richardson et al., 2007) to the risk of AMD in diverse ethnic populations. This might be because of the different ethnic origin of cases and controls, limited sample sizes, and/or limited number of polymorphisms analyzed to ensure a statistically valid conclusion.

Previously, Lu et al. demonstrated no significant associations between VEGF polymorphisms (rs833061, rs1413711, and rs2010963) and the risk of AMD (Lu et al., 2012). However, different observation was indicated in the study by Huang et al. (2013), suggesting the VEGF rs1413711 and rs833061 polymorphisms may contribute to AMD susceptibility. Inconsistent results also implicated different associations between VEGF polymorphisms and various cancers, such as oral squamous cell carcinoma (Supic et al., 2012), colorectal cancer (Jang et al., 2013), gastric cancer (Liu et al., 2011), breast cancer (Wang et al., 2011), and lung cancer (Sun et al., 2013). The controversial data may be due to the disparities in study design and the limited articles included in these analyses. Moreover, the pathogenesis of diseases is complicated and a variety of factors including gene-to-gene and gene-to-environment interactions may be involved in such a progression. Thus, future studies with these interactions considered are required to ascertain the uncertain relationship of VEGF polymorphisms and AMD risk.

Meta-analysis is considered as a powerful tool to identify the associations between polymorphisms and diseases. However, some potential limitations should be acknowledged. First, meta-analysis of pooled data indicated significant heterogeneity across the studies, which may be interpreted by the subjects of various ethnicities and basic methodological differences among the studies. Second, it is impossible to completely rule out the selection bias, because all of the included studies were observational, and confounders of age and gender might have effects on the results. Finally, gene–gene and gene–environment interactions were not addressed in our meta-analysis. Some polymorphisms themselves do not modify disease risks, but the modification would be indicated when interacting with other polymorphisms.

In conclusion, despite the above-mentioned limitations, our results suggest that the VEGF polymorphisms are associated with increased or decreased risk of AMD. In addition, stratified analyses indicate significantly statistical evidence for modified wet AMD risk associated with the TT genotype of the studied polymorphisms. Future large-scale studies are needed to validate the current conclusions.

Author Disclosure Statement

The authors have declared that no competing interests exist.

References

  1. Almeida LN, et al. (2012) Homozygosity for the +674C>T polymorphism on VEGF gene is associated with age-related macular degeneration in a Brazilian cohort. Graefes Arch Clin Exp Ophthalmol 250:185–189 [DOI] [PubMed] [Google Scholar]
  2. Churchill AJ, et al. (2006) VEGF polymorphisms are associated with neovascular age-related macular degeneration. Hum Mol Genet 15:2955–2961 [DOI] [PubMed] [Google Scholar]
  3. DerSimonian R, Laird N. (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188 [DOI] [PubMed] [Google Scholar]
  4. Egger M, et al. (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Ferrara N. (1999) Molecular and biological properties of vascular endothelial growth factor. J Mol Med (Berl) 77:527–543 [DOI] [PubMed] [Google Scholar]
  6. Ferrara N, Gerber HP, LeCouter J. (2003) The biology of VEGF and its receptors. Nat Med 9:669–676 [DOI] [PubMed] [Google Scholar]
  7. Ferris FL, et al. (2005) A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. Arch Ophthalmol 123:1570–1574 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Folkman J. (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186 [DOI] [PubMed] [Google Scholar]
  9. Galan A, et al. (2010) Association of age-related macular degeneration with polymorphisms in vascular endothelial growth factor and its receptor. Ophthalmology 117:1769–1774 [DOI] [PubMed] [Google Scholar]
  10. Goncalves FM, et al. (2010) Vascular endothelial growth factor genetic polymorphisms and haplotypes in women with migraine. DNA Cell Biol 29:357–362 [DOI] [PubMed] [Google Scholar]
  11. Higgins JP, et al. (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Huang C, et al. (2013) Vascular endothelial growth factor A polymorphisms and age-related macular degeneration: a systematic review and meta-analysis. Mol Vis 19:1211–1221 [PMC free article] [PubMed] [Google Scholar]
  13. Jager RD, Mieler WF, Miller JW. (2008) Age-related macular degeneration. N Engl J Med 358:2606–2617 [DOI] [PubMed] [Google Scholar]
  14. Jang MJ, et al. (2013) Prognostic significance of vascular endothelial growth factor gene polymorphisms in patients with colorectal cancer. Int J Clin Oncol 18(6):1032–41 [DOI] [PubMed] [Google Scholar]
  15. Janik-Papis K, et al. (2009) Association between vascular endothelial growth factor gene polymorphisms and age-related macular degeneration in a Polish population. Exp Mol Pathol 87:234–238 [DOI] [PubMed] [Google Scholar]
  16. Jiang Y, et al. (2013) Association between vascular endothelial growth factor +936 C/T gene polymorphism and age-related macular degeneration. J Int Med Res 41:317–324 [DOI] [PubMed] [Google Scholar]
  17. Lin JM, et al. (2008) Vascular endothelial growth factor gene polymorphisms in age-related macular degeneration. Am J Ophthalmol 145:1045–1051 [DOI] [PubMed] [Google Scholar]
  18. Liu H, Wang S, Huang C. (2011) VEGFA+936C/T and −634G/C polymorphisms and gastric cancer risk: a meta-analysis. Asian Pac J Cancer Prev 12:1979–1983 [PubMed] [Google Scholar]
  19. Lu Y, et al. (2012) Pooled-analysis of the associations between three polymorphisms in the VEGF gene and age-related macular degeneration. Mol Biol Rep 39:6547–6553 [DOI] [PubMed] [Google Scholar]
  20. Mantel N, Haenszel W. (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748 [PubMed] [Google Scholar]
  21. Penn JS, et al. (2008) Vascular endothelial growth factor in eye disease. Prog Retin Eye Res 27:331–371 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Qu Y, et al. (2011) Vascular endothelial growth factor gene polymorphisms and risk of neovascular age-related macular degeneration in a Chinese cohort. Ophthalmic Res 45:142–148 [DOI] [PubMed] [Google Scholar]
  23. Richardson AJ, et al. (2007) A tag-single nucleotide polymorphisms approach to the vascular endothelial growth factor-A gene in age-related macular degeneration. Mol Vis 13:2148–2152 [PubMed] [Google Scholar]
  24. Seddon JM, et al. (2011) Risk models for progression to advanced age-related macular degeneration using demographic, environmental, genetic, and ocular factors. Ophthalmology 118:2203–2211 [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Sun SF, et al. (2013) Polymorphism of VEGF-460C/T associated with the risk and clinical characteristics of lung cancer in Chinese population. Med Oncol 30:410. [DOI] [PubMed] [Google Scholar]
  26. Supic G, et al. (2012) Association of VEGF-A genetic polymorphisms with cancer risk and survival in advanced-stage oral squamous cell carcinoma patients. Oral Oncol 48:1171–1177 [DOI] [PubMed] [Google Scholar]
  27. Szaflik JP, et al. (2009) Distribution of the C-460T polymorphism of the vascular endothelial growth factor gene in age-related macular degeneration. Klin Oczna 111:125–127 [PubMed] [Google Scholar]
  28. Ting AY, Lee TK, MacDonald IM. (2009) Genetics of age-related macular degeneration. Curr Opin Ophthalmol 20:369–376 [DOI] [PubMed] [Google Scholar]
  29. Vincenti V, et al. (1996) Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 93:1493–1495 [DOI] [PubMed] [Google Scholar]
  30. Wang K, et al. (2011) Five polymorphisms of vascular endothelial growth factor (VEGF) and risk of breast cancer: a meta-analysis involving 16,703 individuals. Cytokine 56:167–173 [DOI] [PubMed] [Google Scholar]
  31. Yachimski P, Puricelli WP, Nishioka NS. (2009) Patient predictors of histopathologic response after photodynamic therapy of Barrett's esophagus with high-grade dysplasia or intramucosal carcinoma. Gastrointest Endosc 69:205–212 [DOI] [PubMed] [Google Scholar]

Articles from Genetic Testing and Molecular Biomarkers are provided here courtesy of Mary Ann Liebert, Inc.

RESOURCES